In this week’s new postings on Monday, Wednesday, and Friday, Professor Peter Hillmen from Leeds, England outlines the sorry state of traditional trial design and the problems it creates, or more accurately the problems that it doesn’t solve, for us CLL patients. Professor Hillmen heads up CLL research in the United Kingdom.
There are so many new CLL drugs and even more possible combinations that need to be explored. And that can take a long, long time.
But he offers a practical, agile solution that is happening in the United Kingdom.
During the three-part interview, Professor Hillmen outlines a consolidated strategy called TAP (Trials Acceleration Programme) to get us the answers we need more quickly (VIEW HERE). Trial design (VIEW HERE), surrogate markers and how well they translate with novel therapies (VIEW HERE), and statistics are explained during the course of our interview done in December 2014 at the ASH (American Society of Hematology) Annual Meeting in San Francisco.
But I will let Professor Hillmen explain it. His excitement and pride are palpable.
We are all in this together.
Brian Koffman, MD